Hospital-Acquired Complications Especially Dangerous in CKD

This article originally appeared here.
Share this content:
Hospital-Acquired Complications Especially Dangerous in CKD
Hospital-Acquired Complications Especially Dangerous in CKD

FRIDAY, April 28, 2017 (HealthDay News) -- Preventable hospital-acquired complications (HACs) are associated with increased risk of adverse outcomes, especially among patients with chronic kidney disease (CKD), according to a study published online April 27 in Clinical Journal of the American Society of Nephrology.

Babak Bohlouli, from the University of Alberta in Canada, and colleagues examined the correlation of preventable HACs with mortality, length of stay (LOS), and readmission among adults. Data were included for 536,549 hospitalizations, including 45,733 with CKD.

The researchers found that in patients with CKD and at least one preventable HAC, the adjusted odds ratios of mortality during index hospitalization and from hospital discharge to 90 days were 4.67 (95 percent confidence interval [CI], 4.17 to 5.22) and 1.08 (95 percent CI, 0.94 to 1.25), respectively. In patients with one or more preventable HAC, the median incremental LOS was 9.86 days. The odds ratio for readmission was 1.24 (95 percent CI, 1.15 to 1.34) with preventable HAC. Relative to patients without CKD or preventable HAC, the odds ratios for mortality during index hospitalization were 2.22 (95 percent CI, 1.69 to 2.94), 5.26 (95 percent CI, 4.98 to 5.55), and 9.56 (95 percent CI, 7.23 to 12.56), respectively, for patients with CKD with no HAC, without CKD with HACs, and with CKD and HACs.

"Preventable HACs are associated with higher mortality, incremental LOS, and greater risk of readmission, especially in people with CKD," the authors write.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »